An interventional study of rivaroxaban plus aspirin and Aspirin 75 mg daily in Stable Coronary Artery Disease (CAD), Myocardial Infarction, sponsored by Republican Specialized Scientific and Practical Medical Center of Cardiology. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Republican Specialized Scientific and Practical Medical Center of Cardiology · Not applicable, Interventional, and Treatment
This study compares rivaroxaban plus aspirin with aspirin alone in patients with stable coronary artery disease at high ischemic risk. The aim is to evaluate whether the combination therapy better prevents cardiovascular events and to assess its safety.
This study will compare the effectiveness and safety of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease who are at high risk of ischemic events. Participants will be randomly assigned to receive either rivaroxaban combined with aspirin or aspirin alone. The main goal is to determine whether the combination of rivaroxaban and aspirin reduces the risk of cardiovascular events (such as heart attack, stroke, or cardiovascular death) more effectively than aspirin monotherapy, while also assessing bleeding risks and overall safety.
2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.
This study's planned enrollment of 200 is above the median of 150 across 1,314 interventional studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →This is the only study on the registry with Republican Specialized Scientific and Practical Medical Center of Cardiology as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 18 years or older
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rivaroxaban plus aspirin
Aspirin monotherapy.
Drug: Aspirin 75 mg daily
Drug pages: Rivaroxaban · Aspirin
Participants receive rivaroxaban in combination with aspirin.
Aspirin monotherapy.
Composite of cardiovascular death, myocardial infarction, or stroke
Time to first occurrence of cardiovascular death, myocardial infarction, or stroke.
Time frame: From randomization up to 36 months (or the duration of the study)
No study locations are listed for this record.
Start is estimated for Nov 2026; primary completion for Nov 2026, 0 months later.
Of 321 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 0 months is below that.
Counting every sponsor, half of 354 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rivaroxaban · Aspirin